Atricure
ATRC40.1501.81% ( -0.740 )
Q2 FY2026 EarningsQ2 FY26 performance significantly beat consensus across the board, with revenue of $153.6M vs. $151.8M expected and a GAAP EPS of $0.18 vs. a near-break-even $0.00 consensus. Gross margin outperformed at 77.2% (+160 bps vs. mean estimate), driven by favorable product mix and manufacturing efficiencies. Strong growth in Pain Management (+27.8% YoY) and Appendage Management (+14.4% YoY) offset continued headwinds in Minimally Invasive Ablation as physicians transition to PFA catheters.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Atricure(ATRC) predict that the Revenue is 153.6 M (+12.83%), Beat estimate;the EBIT is 9.665 M (+256.1%), Beat estimate;the EPS is 0.18 (+238.5%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.15B12.83%
0.15B11.51%
+0.00B1.32%
EBITExceed expectations
0.01B256.09%
0.00B118.02%
+0.01B138.07%
EPSExceed expectations
0.18238.46%
0.0001100.06%
+0.1799138.40%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf